By using one selected drug with the potential to restore the function of N-methyl-D-aspartate (NMDA) plus 12 more drugs tested against other receptors from the same brain area that have a connection in autism that is α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and dedicator of cytokinesis 4 (DOCK4) (Chanda et al. 2016; Guo et al. 2021; 2023; Kim et al. 2019; Niescier & Lin 2021), we aim to bring innovation and progress to the field of ASD treatment. The gene discussed is DOCK4; the disease is autism.